Arcturus Therapeutics (ARCT)

Healthcare · Biotechnology
$13.74 +6.76% on the day Market cap $353M 52-week range $5.50 to $24.17 Prices as of Oct 11, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Arcturus Therapeutics's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

F

Five factors scored 1 to 9 from ARCT's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation5
Profitability0
Growth0
Financial health8
Cash efficiency0

Results from SEC filings

Fiscal years, from Arcturus Therapeutics's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year20212022202320242025
Revenue$12M$206M$167M$152M$82M
Net income-$204M$9M-$30M-$81M-$66M
Free cash flow-$138M$24M-$21M-$60M-$75M
EPS (diluted)-$7.74$0.35-$1.12-$3.00-$2.40
Operating margin-1641.3%5.9%-46.9%-62.8%-93.0%

Where the revenue comes from

Revenue by products, fiscal 2025. Every breakdown, year by year.

Collaboration Revenue$67M82%
Grant Revenue$15M18%

Superinvestors who own ARCT

From each investor's latest 13F filing (what a 13F shows). 2 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Cliff Asness
AQR Capital Management
Added $5M0.00%Q2 2026
Will Nasgovitz
Heartland Advisors
Trimmed $1M0.07%Q2 2026

Insider buying

Open-market purchases by Arcturus Therapeutics's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of ARCT in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when ARCT trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Arcturus Therapeutics insiders buying the stock?

No open-market insider purchases of ARCT in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Arcturus Therapeutics?

2 of the superinvestors Investingly tracks hold ARCT in their latest 13F, including Cliff Asness, Will Nasgovitz.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.